This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Empel, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Empel, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2449-2454, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.00043-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Molecular Survey of β-Lactamases Conferring Resistance to Newer β-Lactams in Enterobacteriaceae Isolates from Polish Hospitals{triangledown}

Joanna Empel, Anna Baraniak,{dagger} Elzbieta Literacka,{dagger} Agnieszka Mrówka,{dagger} Janusz Fiett, Ewa Sadowy, Waleria Hryniewicz, Marek Gniadkowski,* and the Beta-PL Study Group {ddagger}

National Medicines Institute, 00-725 Warsaw, Poland

Received 11 January 2008/ Returned for modification 23 March 2008/ Accepted 25 April 2008

The first national survey of resistance to newer β-lactams in nosocomial populations of Enterobacteriaceae in Poland was performed. The study covered all nonrepetitive enterobacterial isolates cultured from specimens from inpatients in 13 regional secondary-care hospitals from November 2003 to January 2004. Among 2,388 isolates, the predominant species was Escherichia coli (59.6%), followed by Proteus mirabilis (14.5%) and Klebsiella spp. (8.5%). The frequency of extended-spectrum β-lactamases (ESBLs) was very high, with ESBLs present in 11.1% of all isolates and 40.4% of Klebsiella pneumoniae isolates, the latter value greatly exceeding that for E. coli (2.5%). The contribution of outbreak isolates was significant, resulting, for example, in a particularly high rate of ESBL producers among Serratia marcescens isolates (70.8%). The pool of ESBL types was overwhelmingly dominated (81.7%) by CTX-M-like β-lactamases CTX-M-3 (80.6%) and CTX-M-15, with SHV types (17.5%; SHV-2, SHV-5, and SHV-12) and sporadic TEM-like enzymes (0.7%; TEM-19 and TEM-48) being the next most frequent. Acquired AmpC-type cephalosporinases were observed exclusively in P. mirabilis, in 20.5% of the isolates of this species (compared with the frequency of ESBL producers of 11.5% of P. mirabilis isolates). All these cephalosporinases (CMY-12, CMY-15, and a novel variant, CMY-38) originated from Citrobacter freundii. Four isolates of E. coli (two isolates), K. pneumoniae (one isolate), and P. mirabilis (one isolate) produced class A inhibitor-resistant β-lactamases (TEM-30, TEM-32, TEM-37, and SHV-49), being the first of such producers identified in Poland. The survey documented both specific and more global characteristics of the epidemiology of the β-lactamase-mediated resistance in enterobacteria from Polish hospitals and demonstrated that the ESBL frequency has reached an alarming level.

* Corresponding author. Mailing address: National Medicines Institute, ul. Chelmska 30/34, 00-725 Warsaw, Poland. Phone: (48) 22-851 43 88. Fax: (48) 22-841 29 49. E-mail: gniadkow{at}cls.edu.pl

{triangledown} Published ahead of print on 5 May 2008.

{dagger} These authors contributed equally to this work.

{ddagger} In addition to the authors listed, the Beta-PL Study Group included the following members: J. Bakiera, Voivodship Specialist Hospital, Lublin, Poland; A. Budak, Kraków Specialist Hospital, Kraków, Poland; K. Burdynowski, Voivodship Medical Center, Opole, Poland; K. Golec, Voivodship Hospital No. 2, Rzeszów, Poland; E. Jaworska-Blach, Voivodship Specialist Hospital, Wroclaw, Poland; J. Kochanowska, Voivodship Hospital, Bydgoszcz, Poland; A. Powarzynska, Voivodship Hospital No. 2, Gorzów Wielkopolski, Poland; B. Ruszel, Voivodship Hospital, Koszalin, Poland; E. Sobolewska, Copernicus Specialist Hospital, £ódz, Poland; D. Stankiewicz, Bródno Voivodship Hospital, Warsaw, Poland; M. Szarata, Voivodship Hospital, Poznan, Poland; G. Ziólkowski, St. Barbara Voivodship Specialist Hospital, Sosnowiec, Poland; B. Zaglewska, St. Adalbert Specialist Hospital, Gdansk, Poland; and W. Zulikowski, Voivodship Hospital, £omza, Poland.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2449-2454, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.00043-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hrabak, J., Empel, J., Bergerova, T., Fajfrlik, K., Urbaskova, P., Kern-Zdanowicz, I., Hryniewicz, W., Gniadkowski, M. (2009). International Clones of Klebsiella pneumoniae and Escherichia coli with Extended-Spectrum {beta}-Lactamases in a Czech Hospital. J. Clin. Microbiol. 47: 3353-3357 [Abstract] [Full Text]  
  • Hawkey, P. M., Jones, A. M. (2009). The changing epidemiology of resistance. J Antimicrob Chemother 64: i3-i10 [Abstract] [Full Text]  
  • Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»